X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Xtandi (enzalutamide) becomes the first and only androgen receptor signaling inhibitor approved by the FDA for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with high-risk BCR for metastasis.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
Enzalutamide is an androgen receptor inhibitor, which is being evaluated in phase 1 clinical trials for the treatment of metastatic castration-resistant prostate cancer.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ONConcept® Consortium
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2024
Details:
Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor in combination with Xtandi (enzalutamide) is approved by EMA for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Product Name: Talzenna
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
The acquisition will expand Johnson's ADC portfolio by including ARX517 targeting PSMA for mCRPC, ARX788 targeting human epidermal growth factor receptor 2 for metastatic HER2+ breast cancer, and ARX305 targeting CD-70 for renal cell carcinoma.
Lead Product(s): ARX517,Enzalutamide
Therapeutic Area: Oncology Product Name: ARX517
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $1,900.0 million Upfront Cash: $1,900.0 million
Deal Type: Acquisition January 08, 2024
Details:
Bdenza (enzalutamide) is a small molecule AR inhibitor available in oral solution form, which is approved for the treatment of patients with prostate cancer.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Bdenza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Xtandi (enzalutamide) becomes the first and only androgen receptor signaling inhibitor approved by the FDA for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with high-risk BCR for metastasis.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
Xtandi (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. It decreased proliferation, tumor volume and induced cell death of prostate cancer cells.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
EPI-7386 (masofaniten) is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. It is currently being studied in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Xtandi® (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. It decreased proliferation, tumor volume and induced cell death of prostate cancer cells.
Lead Product(s): Enzalutamide,Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
Xtandi® (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. It decreased proliferation, tumor volume and induced cell death of prostate cancer cells.
Lead Product(s): Enzalutamide,Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
Talzenna (talazoparib) is an oral inhibitor of PARP, which plays a role in DNA damage repair combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Product Name: Talzenna
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: TFS Trial Form Support
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Xtandi® (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. In combination with leuprolide it decreased proliferation, tumor volume and induced cell death of prostate cancer cells.
Lead Product(s): Enzalutamide,Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2023
Details:
Xtandi® (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. It decreased proliferation, tumor volume and induced cell death of prostate cancer cells.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
Details:
Xtandi® (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. It decreased proliferation, tumor volume and induced cell death of prostate cancer cells.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Keytruda® (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Enzalutamide
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
Talzenna (talazoparib) is an oral PARP inhibitor, which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to cancer cell apoptosis.
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Product Name: Talzenna
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. It is currently being studied for CRPC whose tumors have progressed on standard-of-care therapies.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Keytruda (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes (immune system) which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Enzalutamide
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor met its primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared with placebo plus XTANDI.
Lead Product(s): Talazoparib,Enzalutamide
Therapeutic Area: Oncology Product Name: Talzenna
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
Decision to discontinue development of NUV-422 is result of an internal risk-benefit analysis factoring in feedback received from U.S. FDA in partial clinical hold letter for monotherapy Phase 1/2 study and clinical hold letters for its combination Phase 1b/2 studies.
Lead Product(s): NUV-422,Enzalutamide
Therapeutic Area: Oncology Product Name: NUV-422
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
The initial data from 36 patients demonstrate that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily pretreated group of patients.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
XTANDI (enzalutamide), is a prescription medicine used to treat men with prostate cancer that no longer responds to a hormone therapy or surgical treatment to lower testosterone.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Results from the research indicated that EPI-7386 has an IC50 of 421 nM in LNCaP reporter assays, which is a range that is comparable to most LBD inhibitors; however, this agent differs from known agents in that its antitumor activity was maintained in CRPC models.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide, in patients with metastatic prostate cancer progressing on enzalutamide.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: ORIC-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
XTANDI (enzalutamide) is an androgen receptor inhibitor approved in U.S. for treatment of patients with CRPC and mCSPC. ARCHES trial data showed XTANDI plus ADT demonstrated a 61% reduction in risk of radiographic disease progression or death in men with mHSPC.
Lead Product(s): Enzalutamide,Androgen Deprivation Therapy
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
Xtandi will now become widely available for mHSPC, an advanced form of prostate cancer where the cancer has progressed outside the prostate gland.
Lead Product(s): Enzalutamide,Androgen Deprivation Therapy
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
With this indication, XTANDITM (enzalutamide) is now the only oral treatment approved by the EC to treat three distinct types of advanced prostate cancer-non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mHSPC.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2021
Details:
If approved by the European Commission, enzalutamide will be the only oral therapy for the treatment of metastatic hormone-sensitive prostate cancer in addition to non-metastatic and metastatic castration-resistant prostate cancer.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
Panbela’s independent data safety monitoring board (DSMB) recommended SBP-101 be held for ongoing patients in order to obtain additional safety information but will continue with the standard drug regimen.
Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
Panbela has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
The approval is based on results from the PROSPER trial, a double-blind, placebo-controlled, pivotal Phase 3 trial that evaluated enzalutamide plus ADT versus placebo plus ADT in 1,401 men with nmCRPC and rapidly rising prostate-specific antigen levels.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
The data demonstrate that GR may be a mechanism of resistance to AR degraders and that in vitro, ORIC-101 overcomes GR-driven resistance to AR degradation.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: ORC-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Funding will support development of SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for the exocrine pancreas and pancreatic ductal adenocarcinoma.
Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Craig-Hallum Capital Group
Deal Size: $10.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 01, 2020
Details:
MANA RBM and CUSP announced randomization of the first subject in ESCALATE, A Phase III Study Comparing Enzalutamide or Darolutamide with Radium-223 vs Enzalutamide or Darolutamide with Placebo and the Effect upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
Merck, Pfizer, UCSF and Newsoara join the list of collaborators involved in Zenith's development of ZEN-3694 in epigenetic combination therapy programs.
Lead Product(s): ZEN003694,Enzalutamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: ZEN-3694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
Details:
Swedish researchers have initiated a new clinical trial to assess a prostate cancer drug, called Enzalutamide, for the treatment of Covid-19 patients.
Lead Product(s): Enzalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
The company's lead candidate, SBP-101, is a small molecule polyamine metabolic inhibitor delivered subcutaneously for the treatment of pancreatic cancer and solid tumors.
Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 02, 2020
Details:
The company has received Fast Track Designation from the U.S. FDA for its lead product, SBP-101, being developed for firstline treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA) when administered in combination with gemcitabine and nab-paclitaxel.
Lead Product(s): Diethyl dihydroxyhomospermine,Enzalutamide,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
Company enrolled first patient in RELIANT, an open-label, Phase 3 trial of relacorilant in combination with nab-paclitaxel (Celgene’s medication, Abraxane®) in patients with metastatic pancreatic cancer.
Lead Product(s): Relacorilant,Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
The study highlighted full-length AR target engagement by EPI-7386, Its In vitro cellular gene expression analyses, Toxicology studies evaluating the safety profile of EPI-7386 and its starting clinical dose.
Lead Product(s): Masofaniten,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
ORIC-101 overcame GR-mediated resistance to chemotherapeutic agents including taxanes, antimetabolites and platinums, in both in vitro and in vivo efficacy studies spanning a variety of solid tumor types.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: ORC-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Two posters highlighting preclinical data of the company's lead drug candidates, KPG-121 and KPG-818, will be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.
Lead Product(s): KPG-121,Enzalutamide
Therapeutic Area: Oncology Product Name: KPG-121
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
With this approval, XTANDI is now indicated for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), a form of prostate cancer that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
Phase 3 PROSPER trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, revealed that XTANDI plus ADT reduced the risk of death by 27% compared to placebo plus ADT.
Lead Product(s): Enzalutamide,Androgen deprivation therapy
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
Roche conceded that Tecentriq failed to help prostate cancer patients live longer when added to Xtandi, Pfizer and Astellas’ mainstay androgen receptor antagonist.
Lead Product(s): Atezolizumab,Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
The IPO proceeds will push ORIC Pharma's lead program through phase 1b and into phase 2 and move its second program into the clinic.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 23, 2020
Details:
The funding is directed towards company's advancing pipeline of drug candidates for the treatment of prostate cancer and solid tumors.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 20, 2020
Details:
The results demonstrated a statistically significant improvement in OS in patients with nmCRPC who were treated with XTANDI plus ADT.
Lead Product(s): Enzalutamide,Androgen deprivation therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2020
Details:
Study based on preclinical evidence suggesting ORIC-101, may inhibit a potential mechanism of resistance to XTANDI® in patients with metastatic prostate cancer.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
